Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Liabilities and Shareholders Equity (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $53.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 17.28% to $53.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $121.8 million, a 55.44% decrease, with the full-year FY2025 number at $53.0 million, up 17.28% from a year prior.
  • Liabilities and Shareholders Equity was $53.0 million for Q4 2025 at Spruce Biosciences, up from $15.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $139.1 million in Q1 2023 to a low of $15.3 million in Q3 2025.
  • A 4-year average of $79.9 million and a median of $86.6 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 21.36% in 2023, then plummeted 76.48% in 2025.
  • Spruce Biosciences' Liabilities and Shareholders Equity stood at $85.6 million in 2022, then increased by 21.36% to $103.9 million in 2023, then tumbled by 56.51% to $45.2 million in 2024, then rose by 17.28% to $53.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Liabilities and Shareholders Equity are $53.0 million (Q4 2025), $15.3 million (Q3 2025), and $21.8 million (Q2 2025).